← Back to patent-cliff list
Dapolsertib hydrochloride
Tier C — Watch / tradeDapolsertib hydrochloride
Ryvu Therapeutics Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Pim-1, FLT3
Indications (approved)：B-cell lymphoma, Acute myeloid leukaemia
Regional status
US
Phase II
2017-03-10
EU
Phase II
2017-03-10
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dapolsertib hydrochloride?
Approved indications include: B-cell lymphoma, Acute myeloid leukaemia.
When does the Dapolsertib hydrochloride patent expire?
No public expiry year is available for Dapolsertib hydrochloride yet; this page updates once verified.
How do I get a quote for Dapolsertib hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09